Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Granted US Patent Supporting Vasclir Diagnostic; Begins Intended-Use Study for Test

Premium

Vermillion announced this week it has been granted a US patent allowing it to use B2-microglobulin as a biomarker for its peripheral artery disease diagnostic Vasclir and that it has begun an intended-use population study for the test.

The patent, number 7,867,719, covers "biomarker combinations that include B2-microglobulin for the diagnosis and management of peripheral artery disease and to the measurement of the biomarkers by a variety of methods, including mass spectrometry and immunoassay," the company said in a statement.

Also in the statement, CEO Gail Page said that Vermillion continues "to progress in our PAD program, including the initiation of our intended-use study."

The granting of the patent follows on the notice of allowance for it that Vermillion received in September (PM 9/17/2010).

Vasclir is the second test Quest Diagnostics accepted from the company as part of the partners' three-test strategic alliance agreement. The first was the ovarian cancer assay OVA1.

During the company's second-quarter earnings call in August, chief science officer Eric Fung said developing Vasclir is one of Vermillion's primary R&D focuses, and noted the firm planned to begin an intended-use population study for the test by the end of 2010 (PM 08/13/2010).

According to Fung, PAD currently affects some 12 million Americans, a number that is expected to rise as the incidence of diabetes increases.

During the August earnings call, Page said that a commercial launch of Vasclir is likely still several years away.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.